News · 26 weeks1080%
2026-04-192026-10-11
Mix3690d
- SEC Filings13(36%)
- Other12(33%)
- Insider8(22%)
- Earnings3(8%)
Latest news
25 items- INSIDERSEC Form 3 filed by Seer Inc.3 - Seer, Inc. (0001726445) (Issuer)
- PRSeer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) today announced that researchers from Nanyang Technological University will present early findings from the PRECISE-SG100K study at the 2026 Human Proteome Organization (HUPO) World Congress, taking place September 27 to October 1 at the Suntec Singapore Convention & Exhibition Centre. Led by John Chambers, PhD, Chief Scientific Officer of PRECISE and Lead PI of PRECISE-SG100K, the study represents an ambitious effort to bring deep molecular characterization to population health at unprecedented scale. By integrating proteomic data with genomic, clinical and phenotypic information from Singapore's multi-ethn
- PRSeer Announces CFO TransitionREDWOOD CITY, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that David Horn, the Company’s President, Chief Financial Officer and Treasurer, will depart Seer effective October 1, 2026, to pursue a new opportunity at a private company. Charles Endweiss, who has been Seer’s Vice President, Financial Planning & Analysis, will serve as Treasurer, principal financial officer and principal accounting officer, effective October 1, 2026. "David has been an important member of Seer’s leadership team for more than six years, helping guide the Company through a piv
- SECSEC Form 8-K filed by Seer Inc.8-K - Seer, Inc. (0001726445) (Filer)
- PRSeer Surpasses 100 Peer-Reviewed Customer Publications, Validating a New Era of Deep Proteomics at ScaleREDWOOD CITY, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a pioneer in deep, unbiased proteomics, today announced that its Proteograph® Product Suite has been used by researchers in more than 100 peer-reviewed scientific publications, enabling researchers to uncover differentiated proteomic insights and marking a significant milestone in the emergence of deep proteomics at scale as a new paradigm for biological research. For decades, proteomics researchers faced a fundamental tradeoff: they could interrogate the proteome deeply or study large numbers of samples, but doing both was impractical. Seer was founded to eliminate that compromise. By combining engineered
- PRRadoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.’s Board of DirectorsBelieves Ms. Gulyani Is Not Qualified to Serve on the Board and That Her Membership on the Special Committee Has Not Served Stockholders’ Best Interests Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ:SEER), today issued the following open letter to director Meeta Gulyani. *** September 4, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: Meeta Gulyani Dear Ms. Gulyani, As you know, we are significant stockholders of Seer, Inc. ("Seer" or the "Company"), collectively owning approximately 7.7% of the Company’s outstanding shares. We respectfully request that you immedi
- INSIDERPRESIDENT & CFO Horn David R. sold $14,809 worth of shares (7,309 units at $2.03), decreasing direct ownership by 1% to 486,650 units (SEC Form 4) to cover taxes4 - Seer, Inc. (0001726445) (Issuer)
- PRRadoff-JEC Group Calls on Seer, Inc.’s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition OffersBelieves Special Committee Is Not Truly Interested in Running a Robust Auction Based on its Tepid Engagement to Date Continues to Believe – Consistent with Chairman and CEO Omid Farokhzad – Seer Should Not Remain a Public Company Given its Lack of a Credible Plan to Create Value for Stockholders and Q2 2026 Earnings, Which Reflected Lower Sales, Lower Gross Profit and Shrinking Cash Reserves Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ:SEER) (the "Company"), today issued the following open letter to the Company’s Board of Directors. *** August 13, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood
- SECSEC Form 10-Q filed by Seer Inc.10-Q - Seer, Inc. (0001726445) (Filer)
- SECSeer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Seer, Inc. (0001726445) (Filer)
- PRSeer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 OutlookREDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended June 30, 2026. Recent Highlights Achieved revenue of $3.1 million in the second quarter of 2026Our collaborators from Korea University presented preliminary data at the 74th American Society for Mass Spectrometry Conference (ASMS), demonstrating potential of AI-driven plasma proteomics for multi-cancer screeningProteograph leveraged in an independent study published in Nature Genetics, "Nanoparticle-enriched mass spectrometry proteomics in British South As
- PRSeer to Participate in the Canaccord Genuity 46th Annual Growth ConferenceREDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston, MA. Seer’s management is scheduled to present on Wednesday, August 12th from 8:00 a.m. to 8:25 a.m. Eastern Time / 5:00 a.m. to 5:25 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference. About SeerSeer, Inc. (NASDAQ:SEER) sets the standard in deep,
- PRSeer to Report Second Quarter 2026 Financial Results on August 11, 2026REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2026 on Tuesday, August 11, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event. About SeerSeer, Inc. (NASDAQ:SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, p
- SECSeer Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Seer, Inc. (0001726445) (Filer)
- SECSeer Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Seer, Inc. (0001726445) (Filer)
- PRSeer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.REDWOOD CITY, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that on July 28, 2026, it received a further revised, unsolicited, non-binding acquisition proposal from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group") to acquire all of the outstanding shares of Seer’s Class A common stock for $2.55 per share in cash plus a contingent value right. On July 29, 2026, Seer received a revised, unsolicited, non-binding acquisition proposal from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstand
- INSIDERDirector Roelofs Nicolas H Phd was granted 16,500 shares, increasing direct ownership by 22% to 91,496 units (SEC Form 4)4 - Seer, Inc. (0001726445) (Issuer)
- INSIDERDirector Ro Isaac was granted 12,375 shares, increasing direct ownership by 30% to 53,375 units (SEC Form 4)4 - Seer, Inc. (0001726445) (Issuer)
- INSIDERDirector Nishar Dipchand was granted 16,500 shares, increasing direct ownership by 28% to 75,544 units (SEC Form 4)4 - Seer, Inc. (0001726445) (Issuer)
- INSIDERDirector Mcguire Terrance was granted 16,500 shares, increasing direct ownership by 15% to 128,566 units (SEC Form 4)4 - Seer, Inc. (0001726445) (Issuer)
- INSIDERDirector Langer Robert was granted 16,500 shares, increasing direct ownership by 2% to 821,025 units (SEC Form 4)4 - Seer, Inc. (0001726445) (Issuer)
- INSIDERDirector Gulyani Meeta was granted 16,500 shares, increasing direct ownership by 15% to 124,043 units (SEC Form 4)4 - Seer, Inc. (0001726445) (Issuer)
- PRSeer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual MeetingREDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer") today announced that, based on the preliminary voting results from Seer’s 2026 Annual Meeting of Stockholders (the "Annual Meeting"), Seer stockholders have voted to re-elect all seven of Seer’s director nominees – Omid Farokhzad, M.D.; Meeta Gulyani; Robert Langer, Sc.D.; Terrance McGuire; Dipchand (Deep) Nishar; Isaac Ro; and Nicolas Roelofs, Ph.D. – to Seer’s Board of Directors (the "Board"). Seer issued the following statement: We thank our stockholders for their support and engagement over the last several months. This outcome reflects confidence in Seer’s highly qualified, purpose-built Board
- SECSEC Form DFAN14A filed by Seer Inc.DFAN14A - Seer, Inc. (0001726445) (Subject)
- PRRadoff-JEC Group Submits Further Improved Proposal to Acquire Seer, Inc.Proposal Provides Stockholders $2.55 per Share in Cash, a 51% Premium to the Unaffected Share Price and 29% Premium to the Current Share Price, as Well as Potential Additional Value from the Sale of Seer’s Assets via a Contingent Value Right Urges Seer’s Two-Member Special Committee to Conduct an Auction and Avoid Further Value Destruction Under the Leadership of Chairman and CEO Omid Farokhzad, M.D. Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ:SEER) (the "Company"), today submitted the following improved non-binding proposal to acquire the Company – their fourth such proposal – for $2.55 per share in cash p
SEER FAQ
7 questionsWhat does Seer Inc. do?
Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology...Where does SEER stock trade?
Seer Inc. (SEER) is listed on NASDAQ.What sector and industry is SEER in?
Seer Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Seer Inc. go public?
Seer Inc. (SEER) completed its IPO in 2020.What are analysts saying about SEER?
Seer Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $400.00 price target on 2026-05-04.What companies are similar to SEER?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare SEER side-by-side with any of them on Quantisnow.How can I track SEER on Quantisnow?
Quantisnow aggregates Seer Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SEER to receive live email and push alerts on every new disclosure.